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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
This review aims to look at the effect of NSAIDs used in the peri-operative period on post-operative kidney function in patients with
normal kidney function.
B A C K G R O U N D
Description of the condition
There is increasing evidence that acute kidney injury (AKI) is as-
sociated with both short- and long-term adverse consequences.
These include increased length of hospital stay, mortality and fu-
ture development of chronic kidney disease (CKD) evenwith small
transient rises in serum creatinine (Bucaloiu 2012; Chertow 2005;
Coca 2012; Lassnigg 2004). Surgery is a leading cause of AKI in
hospitalised patients (Carmichael 2003).
Effective management of post-operative pain is extremely impor-
tant. It facilitates earlymobilisation thereby reducing hospital costs
through shortened duration of hospital in-patient stay, reduces
pulmonary and cardiovascular complications and risk of deep vein
thrombosis. In addition, it impacts on quality of patient care by
relieving suffering and distress and improving satisfaction. The
major aim of post-operative pain management is providing ad-
equate pain relief using the minimal possible dose thereby min-
imising adverse effects. Clinical guidelines for managing periop-
erative pain were updated in 2012 by the American Society of
Anesthesiologists Task Force on Acute Pain Management. It rec-
ommends a multimodal approach to post-operative pain includ-
ing the use of both nonselective nonsteroidal anti-inflammatory
drugs; (NSAIDs) as well as selective NSAIDs (Cox-2 inhibitors)
(ASAPracticeGuideline 2012).NSAIDs can affect the kidneys in a
number of ways. This includes haemodynamically mediated AKI,
electrolyte and acid-base disorders and acute interstitial nephritis.
These adverse effects are thought to occur in 1% to 5% of all pa-
tients using NSAIDs (Whelton 1999).
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Description of the intervention
NSAIDs inhibit prostaglandin synthesis by inhibiting cyclooxyge-
nase-1 (Cox-1) and cyclooxygenase -2 (Cox-2). Cox-1 is expressed
in most tissues regulating normal cellular processes such as gastric
cytoprotection, vascular homeostasis, platelet aggregation and kid-
ney function. Cox-2 is expressed in brain, kidney and bone. Most
traditionalNSAIDs are non-selective inhibitors of bothCox-1 and
Cox-2. Selective Cox-2 inhibitors include celecoxib, rofecoxib and
valdecoxib.
Cyclooxgenases are produced at multiple sites within the kidney
including glomerular and vascular endothelium, medullary and
cortical collecting tubules and medullary interstitial cells. Cox-
1 is expressed in most tissues and Cox-2 is expressed at low
levels increasing with stimulation such as inflammation. Renal
prostaglandins are primarily vasodilators in the kidneys. Under
normal circumstances, renal prostaglandins do not contribute to
regulation of kidney perfusion but in the setting of hypotension
and reduced kidney perfusion fromvasoconstrictionprostaglandin
synthesis is increased to maintain kidney perfusion and mini-
mize ischaemia. Other kidney effects of prostaglandins include in-
creased renin secretion, antagonism of anti-diuretic hormone ef-
fects and increased sodium excretion.
How the intervention might work
The use of both non-selective and selective NSAIDs for post-op-
erative pain has been evaluated in a number of Cochrane reviews.
A single dose of ibuprofen lead to at least 50% pain relief in ap-
proximately half of patients with moderate to severe postoperative
pain. Adverse effects were similar to placebo (Derry 2009). Aspirin
was found to confer a 50% or greater reduction in pain in 39%
of those with moderate to severe pain, compared with 15% of
those in the placebo group. Adverse events were similar for those
taking a lower dose aspirin (600 mg or 650 mg). However, higher
dose aspirin (900 mg to 1000 mg) experienced adverse events at
more than twice the rate of patients receiving placebo (26% ver-
sus 12%) (Derry 2012a) . The use of a single dose of the Cox-2
inhibitor celecoxib in the treatment of acute post-operative pain
showed that 33% of patients receiving celecoxib 200mg, and 44%
receiving 400 mg, experienced at least 50% pain relief, compared
with between 1% and 11% of patients receiving placebo. Adverse
events were similar in the celecoxib and placebo groups (Derry
2012b).
Furthermore, there is evidence supporting the efficacy of NSAIDs
for post-operative pain with studies demonstrating opioid sparing
effects (McDaid 2010).
NSAIDs have the potential to adversely affect kidney function in
the peri-operative setting. Pre-renal insults such as hypovolaemia
or hypotension peri-operatively cause NSAID-induced inhibition
of prostaglandin mediated afferent arteriolar dilatation leading to
reduced glomerular perfusion. The risk of AKI with NSAIDs has
led the Medicines and Healthcare Products Regulatory Agency to
issue drug safety advice recommending that NSAIDs be avoided
in patients with hypovolaemia (MHRA 2009).
Why it is important to do this review
This will expand on the Cochrane review last published in 2007
(Lee 2007). This review showed that NSAIDs caused a clinically
unimportant transient reduction in kidney function in the early
post-operative period in patients with normal kidney function.
Since its publication, a universal definition for AKI has been devel-
oped allowing a better understanding of its epidemiology and clin-
ical significance (KDIGO 2012). Since the advent of the KDIGO
definition for AKI, there is increasing evidence of the adverse clin-
ical and economic consequences of AKI. In addition, National In-
stitute for Clinical Excellence (NICE) AKI guidance recommends
the avoidance of NSAIDs in the post-operative period (Ftouh
2013).
It is therefore important to re-assess the renal safety of NSAIDs in
the peri-operative period.
O B J E C T I V E S
This review aims to look at the effect of NSAIDs used in the peri-
operative period on post-operative kidney function in patients
with normal kidney function.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) and quasi-RCTs (RCTs
in which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods) looking at the use of NSAIDS versus placebo for the
treatment of post-operative pain in patients with normal kidney
function will be included. As we are looking at an adverse event,
we will also examine cohort studies which report on the risk of
AKI associated with NSAIDs use in the peri-operative period.
However, results from cohort studies will be analysed separately
from RCTs.
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Types of participants
People of at least 18 years of age undergoing surgical procedures
who were treated with NSAIDs or Cox-2 inhibitors with normal
kidney function will be included. Normal kidney function is de-
fined as estimated glomerular filtration rate (eGFR) greater than
60 mL/min/1.73 mm² without other evidence of kidney disease
(proteinuria, haematuria, genetic kidney disease or structural kid-
ney abnormalities).
Types of interventions
All interventions comparing NSAID treatments including Cox-2
inhibitors versus placebo will be considered. Variable doses and all
routes of administration will be considered.
Types of outcome measures
Primary outcomes
The primary outcome will be AKI as defined by KDIGOwhich is
based on serum creatinine or urine output (KDIGO2012). Serum
creatinine and urine output based AKI criteria will be analysed
both separately and together depending on the number of eligible
studies.
Secondary outcomes
1. All-cause mortality
2. Length of hospital stay
3. Need for renal replacement therapy (RRT).
Search methods for identification of studies
Electronic searches
We will search the Cochrane Renal Group’s Specialised Register
through contact with the Trials’ Search Co-ordinator using search
terms relevant to this review. The Cochrane Renal Group’s Spe-
cialised Register contains studies identified from the following
sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the
proceedings of major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies, as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts, are available in the Specialised
Register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts will be screened independently by two authors, who
will discard studies that are not applicable, however studies and
reviews that might include relevant data or information on studies
will be retained initially. Two authors will independently assess
retrieved abstracts and, if necessary the full text, of these studies
to determine which studies satisfy the inclusion criteria.
Data extraction and management
Data extraction will be carried out independently by two authors
using standard data extraction forms. Studies reported in non-
English language journals will be translated before assessment.
Where more than one publication of one study exists, reports will
be grouped together and the publication with the most complete
data will be used in the analyses. Where relevant outcomes are
only published in earlier versions these data will be used. Any
discrepancy between published versions will be highlighted.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
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• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
As suggested in the Cochrane Handbook for Systematic Reviews of
Interventions, (section 13.5, Higgins 2011) the Newcastle-Ottawa
scale for assessing risk of bias of non-randomised studies will be
used (Wells 2014). Although the score does not classify the studies
according to study quality, the most appropriate scale - the New-
castle-Ottawa Scale for Cohort studies (Appendix 3; Appendix 4)
identifies issues with three domains. These three domains looking
at selection (or representativeness of cohorts), comparability (of
cohorts due to design or analysis) and outcomes (assessment and
follow up) are further subdivided into eight questions, which will
be represented in the review’s risk of bias tables inCharacteristics of
included studies. In the Scale, a high-quality choice is represented
by a star. The selection, comparability and outcome domains have
4, 1 and 3 possible stars respectively.
Appropriate selection criteria of cohorts will be considered to be
consecutive series of patients with the controls from the same or
similar population. When assessing comparability, a star will be
given for matching on age and criteria for the follow up domain to
receive stars were that the primary outcome of mortality needed
to be included, follow-up to be at least one year and greater than
80% of the original cohort followed to be of high quality.
The overall rating that will be given was based on the number of
stars attained. A rating of high requires eight stars, moderate level
cohort studies requires a score of six to seven stars, low level four
or five5 stars and very low level score three stars or less.
Measures of treatment effect
For dichotomous outcomes such as need for RRT, results will
be expressed as risk ratio (RR) with 95% confidence intervals
(CI). Where continuous scales of measurement are used to assess
the effects of treatment such as length of hospital stay, the mean
difference (MD) will be used, or the standardised mean difference
(SMD) if different scales have been used.
Unit of analysis issues
We do not expect to find relevant cluster-randomised studies so
do not anticipate that unit of analysis issues will arise.
Dealing with missing data
Any further information required from the original author will
be requested by written correspondence (e.g. emailing the corre-
sponding author/s) and any relevant information obtained in this
manner will be included in the review. Evaluation of important
numerical data such as screened, randomised patients as well as
intention-to-treat, as-treated and per-protocol population will be
carefully performed. Attrition rates, for example drop-outs, losses
to follow-up and withdrawals will be investigated. Issues of miss-
ing data and imputation methods (for example, last-observation-
carried-forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
Heterogeneity will be analysed using a Chi² test on N-1 degrees
of freedom, with an alpha of 0.05 used for statistical significance
and with the I² test (Higgins 2003). I² values of 25%, 50% and
75% correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixed-
effect model will also be used to ensure robustness of the model
chosen and susceptibility to outliers. Data synthesis will be done
separately for RCTs and cohort studies.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be used to explore possible sources of het-
erogeneity such as type of surgery. Heterogeneity among partici-
pants could be related to age. Heterogeneity in treatments could
be related to agent (Cox-1 versus Cox-2 inhibitors), dose and du-
ration of therapy. In addition, exclusion criteria of studies will
be examined to assess for heterogeneity in particular risk factors
for post-operative AKI according to NICE and KDIGO guid-
ance (Ftouh 2013; KDIGO 2012). These include intraperitoneal
surgery, CKD, diabetes mellitus, chronic disease, advanced age,
cancer, anaemia or black race. Adverse effects will be tabulated
and assessed with descriptive techniques, as they are likely to be
different for the various agents used. Where possible, the risk dif-
ference with 95% CI will be calculated for each adverse effect,
either compared to no treatment or to another agent.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
4Effects of peri-operative nonsteroidal anti-inflammatory drugs on postoperative kidney function for adults with normal kidney function
(Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
A C K N OW L E D G E M E N T S
We would like to thank the referees for their feedback and advice
during the preparation of this protocol.
R E F E R E N C E S
Additional references
ASA Practice Guideline 2012
American Society of Anesthesiologists Task Force on Acute
Pain Management. Practice guidelines for acute pain
management in the perioperative setting: an updated report
by the American Society of Anesthesiologists Task Force
on Acute Pain Management. Anesthesiology 2012;116(2):
248–73. [MEDLINE: 22227789]
Bucaloiu 2012
Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE 2nd,
Perkins RM. Increased risk of death and de novo chronic
kidney disease following reversible acute kidney injury.
Kidney International 2012;81(5):477–85. [MEDLINE:
22157656]
Carmichael 2003
Carmichael P, Carmichael AR. Acute renal failure in the
surgical setting. ANZ Journal of Surgery 2003;73(3):
144–53. [MEDLINE: 12608979]
Chertow 2005
Chertow GM, Burdick E, Honour M, Bonventre JV, Bates
DW. Acute kidney injury, mortality, length of stay, and
costs in hospitalized patients. Journal of the American
Society of Nephrology 2005;16(11):3365–70. [MEDLINE:
16177006]
Coca 2012
Coca SG, Singanamala S, Parikh CR. Chronic kidney
disease after acute kidney injury: a systematic review and
meta-analysis. Kidney International 2012;81(5):442–8.
[MEDLINE: 22113526]
Derry 2009
Derry CJ, Derry S, Moore RA, McQuay HJ. Single dose
oral ibuprofen for acute postoperative pain in adults.
Cochrane Database of Systematic Reviews 2009, Issue 3.
[DOI: 10.1002/14651858.CD001548.pub2]
Derry 2012a
Derry S, Moore RA. Single dose oral aspirin for acute
postoperative pain in adults. Cochrane Database of
Systematic Reviews 2012, Issue 4. [DOI: 10.1002/
14651858.CD002067.pub2]
Derry 2012b
Derry S, Moore RA. Single dose oral celecoxib for
acute postoperative pain in adults. Cochrane Database
of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/
14651858.CD004233.pub3]
Ftouh 2013
Ftouh S, Thomas M, Acute Kidney Injury Guideline
Development Group. Acute kidney injury: summary of
NICE guidance. BMJ 2013;347:f4930. [MEDLINE:
23985310]
Higgins 2003
Higgins JP, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ 2003;327
(7414):557–60. [MEDLINE: 12958120]
Higgins 2011
Higgins JP, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
KDIGO 2012
KDIGO (Kidney Disease: Improving Global Outcomes)
Acute Kidney Injury Work Group. KDIGO clinical practice
guideline for acute kidney injury. Kidney International -
Supplement 2012;2(1):1–138.
Lassnigg 2004
Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann
LM, Druml W, Bauer P, et al. Minimal changes of serum
creatinine predict prognosis in patients after cardiothoracic
surgery: a prospective cohort study. Journal of the American
Society of Nephrology 2004;15(6):1597–605. [MEDLINE:
15153571]
Lee 2007
Lee A, Cooper MG, Craig JC, Knight JF, Keneally
JP. Effects of nonsteroidal anti-inflammatory drugs on
postoperative renal function in adults with normal renal
function. Cochrane Database of Systematic Reviews 2007,
Issue 2. [DOI: 10.1002/14651858.CD002765.pub3]
McDaid 2010
McDaid C, Maund E, Rice S, Wright K, Jenkins B,
Woolacott N. Paracetamol and selective and non-selective
5Effects of peri-operative nonsteroidal anti-inflammatory drugs on postoperative kidney function for adults with normal kidney function
(Protocol)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
non-steroidal anti-inflammatory drugs (NSAIDs) for
the reduction of morphine-related side effects after
major surgery: a systematic review. Health Technology
Assessment (Winchester, England) 2010;14(17):1-153, iii-iv.
[MEDLINE: 20346263]
MHRA 2009
Medicines and Healthcare Products Regulatory Agency.
Drug Safety Update: Volume 2 Issue 10, May
2009. www.mhra.gov.uk/Publications/Safetyguidance/
DrugSafetyUpdate/CON046451 Vol. (accessed 17 August
2014).
Wells 2014
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos
M, et al. The Newcastle-Ottawa Scale (NOS) for assessing
the quality of non-randomised studies in meta-analyses.
http://www.ohri.ca/programs/clinical_epidemiology/
oxford.asp (accessed 17 August 2014).
Whelton 1999
Whelton A. Nephrotoxicity of nonsteroidal anti-
inflammatory drugs: physiologic foundations and clinical
implications. American Journal of Medicine 1999;106(5B):
13S–24S. [MEDLINE: 10390124]
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
2. ((non-steroidal next anti-inflammatory) next (agent* or drug*)):ti,ab,kw
3. ((nonsteroidal next anti-inflammatory) next (agent* or drug*)):ti,ab,kw
4. ((non-steroidal next antiinflammatory) next (agent* or drug*)):ti,ab,kw
5. ((nonsteroidal next antiinflammatory) next (agent* or drug*)):ti,ab,kw
6. NSAID*:ti,ab,kw
7. ((cox 2 inhibitor*) or (cox-2 inhibitor*)):ti,ab,kw
8. (cyclooxygenase near/2 Inhibitor*):ti,ab,kw
9. apazone:ti,ab,kw
10. aspirin:ti,ab,kw
11. clonixin:ti,ab,kw
12. diclofenac:ti,ab,kw
13. diflunisal:ti,ab,kw
14. epirizole:ti,ab,kw
15. fenoprofen:ti,ab,kw
16. feprazone:ti,ab,kw
17. flurbiprofen:ti,ab,kw
18. ibuprofen:ti,ab,kw
19. indomethacin:ti,ab,kw
20. ketoprofen:ti,ab,kw
21. ketorolac:ti,ab,kw
22. meclofenamic acid:ti,ab,kw
23. mefenamic acid:ti,ab,kw
24. naproxen:ti,ab,kw
25. niflumic acid:ti,ab,kw
26. phenylbutazone:ti,ab,kw
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(Continued)
27. piroxicam:ti,ab,kw
28. salicylates:ti,ab,kw
29. sulindac:ti,ab,kw
30. tolmetin:ti,ab,kw
31. celecoxib:ti,ab,kw
32. etodolac:ti,ab,kw
33. meloxicam:ti,ab,kw
34. parecoxib:ti,ab,kw
35. rofecoxib:ti,ab,kw
36. tenoxicam:ti,ab,kw
37. valdecoxib:ti,ab,kw
38. {or #1-#37}
39. analgesi*:ti,ab,kw
40. an*esthesia:ti,ab,kw
41. pain:ti,ab,kw
42. (peri-operativ* or perioperativ*):ti,ab,kw
43. (postoperativ* or post-operativ*):ti,ab,kw
44. (preoperativ* or pre-operativ*):ti,ab,kw
45. {or #39-#44}
46. kidney:ti,ab,kw
47. renal:ti,ab,kw
48. creatinine:ti,ab,kw
49. nephrotoxi*:ti,ab,kw
50. azot*emia:ti,ab,kw
51. dialysis:ti,ab,kw
52. (hemodia* or haemodia* or hemofiltr* or haemofiltr*):ti,ab,kw
53. (“glomerular filtration rate” or “glomerulus filtration rate”):ti,ab,kw
54. (gfr or egfr):ti,ab,kw
55. (urin* near/2 (volume or output)):ti,ab,kw
56. {or #46-#55}
57. {and #38, #45, #56}
58. MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees and with qualifier(s): [Adverse
effects - AE]
59. {and #45, #58}
60. {or #57, #59}
MEDLINE 1. exp Anti-Inflammatory Agents, Non-Steroidal/
2. (non-steroidal anti-inflammatory adj (agent* or drug*)).tw.
3. (nonsteroidal anti-inflammatory adj (agent* or drug*)).tw.
4. (non-steroidal antiinflammatory adj (agent* or drug*)).tw.
5. (nonsteroidal antiinflammatory adj (agent* or drug*)).tw.
6. NSAID*.tw.
7. cox 2 inhibitor*.tw.
8. (cyclooxygenase adj2 Inhibitor*).tw.
9. apazone.tw.
10. aspirin.tw.
11. clonixin.tw.
12. diclofenac.tw.
13. diflunisal.tw.
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(Continued)
14. epirizole.tw.
15. fenoprofen.tw.
16. feprazone.tw.
17. flurbiprofen.tw.
18. ibuprofen.tw.
19. indomethacin.tw.
20. ketoprofen.tw.
21. ketorolac.tw.
22. meclofenamic acid.tw.
23. mefenamic acid.tw.
24. naproxen.tw.
25. niflumic acid.tw.
26. phenylbutazone.tw.
27. piroxicam.tw.
28. salicylates.tw.
29. sulindac.tw.
30. tolmetin.tw.
31. celecoxib.tw.
32. etodolac.tw.
33. tenoxicam.tw.
34. parecoxib.tw.
35. rofecoxib.tw.
36. meloxicam.tw.
37. valdecoxib.tw.
38. or/1-37
39. exp Analgesia/
40. analgesi*.tw.
41. an?esthesia.tw.
42. Pain/
43. Acute Pain/
44. Pain, Postoperative/
45. Pain Management/
46. Perioperative Period/
47. Postoperative Period/
48. (peri-operative or perioperative).tw.
49. (postoperative or post-operative).tw.
50. Preoperative Period/
51. (preoperative or pre-operative).tw.
52. Postoperative Complications/
53. pain.tw.
54. /39-53
55. and/38,54
56. Kidney/
57. Kidney Diseases/
58. Renal Insufficiency/
59. exp Acute Kidney Injury/
60. Creatinine/
61. Kidney Function Tests/
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62. (kidney* or renal).tw.
63. creatinine.tw.
64. (nephrotox*).tw.
65. azot?emia.tw.
66. Renal Replacement Therapy/
67. exp Renal Dialysis/
68. dialysis.tw.
69. (hemodia* or haemodia* or hemofiltr* or haemofiltr*).tw.
70. glomerular filtration rate.tw.
71. (gfr or egfr).tw.
72. (urin* adj2 (volume or output)).tw.
73. or/56-72
74. and/55,73
75. exp Anti-Inflammatory Agents, Non-Steroidal/ae
76. and/54,75
77. or/74,76
EMBASE 1. exp nonsteroid antiinflammatory agent/
2. (non-steroidal anti-inflammatory adj (agent* or drug*)).tw.
3. (nonsteroidal anti-inflammatory adj (agent* or drug*)).tw.
4. (non-steroidal antiinflammatory adj (agent* or drug*)).tw.
5. (nonsteroidal antiinflammatory adj (agent* or drug*)).tw.
6. NSAID*.tw.
7. exp Cyclooxygenase 2 Inhibitor/
8. cox 2 inhibitor*.tw.
9. (cyclooxygenase adj2 Inhibitor*).tw.
10. apazone.tw.
11. aspirin.tw.
12. clonixin.tw.
13. diclofenac.tw.
14. diflunisal.tw.
15. epirizole.tw.
16. fenoprofen.tw.
17. feprazone.tw.
18. flurbiprofen.tw.
19. ibuprofen.tw.
20. indomethacin.tw.
21. ketoprofen.tw.
22. ketorolac.tw.
23. meclofenamic acid.tw.
24. mefenamic acid.tw.
25. naproxen.tw.
26. niflumic acid.tw.
27. phenylbutazone.tw.
28. piroxicam.tw.
29. salicylates.tw.
30. sulindac.tw.
31. tolmetin.tw.
32. celecoxib.tw.
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33. etodolac.tw.
34. tenoxicam.tw.
35. parecoxib.tw.
36. rofecoxib.tw.
37. meloxicam.tw.
38. valdecoxib.tw.
39. or/1-38
40. exp Analgesia/
41. analgesi*.tw.
42. an?esthesia.tw.
43. Pain/
44. Postoperative Pain/
45. Postoperative Period/
46. Postoperative Analgesia/
47. Perioperative Period/
48. Preoperative Period/
49. Postoperative Complication/
50. (postoperative or post-operative).tw.
51. (peri-operative or perioperative).tw.
52. (preoperative or pre-operative).tw.
53. pain.tw.
54. or/40-53
55. and/39,54
56. Kidney/
57. Kidney Disease/
58. Kidney Failure/
59. Acute Kidney Failure/
60. Creatinine/
61. Kidney Function/
62. Kidney Function Test/
63. (kidney or renal).tw.
64. creatinine.tw.
65. (nephrotox*).tw.
66. azot?emia.tw.
67. exp Renal Replacement Therapy/
68. dialysis.tw.
69. (hemodia* or haemodia* or hemofiltr* or haemofiltr*).tw.
70. Glomerulus Filtration Rate/
71. glomerular filtration rate.tw.
72. (gfr or egfr).tw.
73. Urine Volume/
74. ((urin* adj2 volume) or output).tw.
75. or/56-74
76. and/55,75
77. exp nonsteroid antiinflammatory agent/ae
78. and/54,77
79. or/76,78
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Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
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(Continued)
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
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High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
Appendix 3. Risk of bias assessment - Newcastle Ottawa Scale Form
Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A
maximum of two stars can be given for comparability.
Selection
1. Representativeness of the exposed cohort
a. truly representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙˙˙ (describe) in the community *
b. somewhat representative of the average ˙˙˙˙˙˙˙˙˙˙˙˙˙˙ in the community *
c. selected group of users (e.g. nurses, volunteers)
d. no description of the derivation of the cohort
2. Selection of the non exposed cohort
a. drawn from the same community as the exposed cohort *
b. drawn from a different source
c. no description of the derivation of the non exposed cohort
3. Ascertainment of exposure
a. secure record (e.g. surgical records) *
b. structured interview *
c. written self report
d. no description
4. Demonstration that outcome of interest was not present at start of study
a. yes *
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b. no
Comparability
1. Comparability of cohorts on the basis of the design or analysis
a. study controls for ˙˙˙˙˙˙˙˙˙˙˙˙˙ (select the most important factor) *
b. study controls for any additional factor * (This criteria could be modified to indicate specific control for a second important factor.)
Outcome
1. Assessment of outcome
a. independent blind assessment *
b. record linkage *
c. self report
d. no description
2. Was follow-up long enough for outcomes to occur
a. yes (select an adequate follow up period for outcome of interest) *
b. no
3. Adequacy of follow up of cohorts
a. complete follow up - all subjects accounted for *
b. subjects lost to follow-up unlikely to introduce bias - small number lost - <15 % follow-up, or description provided of those lost) *
c. follow-up rate < 85% and no description of those lost
d. no statement
Appendix 4. Risk of bias assessment - Newcastle Ottawa Scale
Coding manual for cohort studies
Selection
1. Representativeness of the exposed cohort
Item is assessing the representativeness of exposed individuals in the community, not the representativeness of the sample of women
from some general population. For example, subjects derived from groups likely to contain middle class, better educated, health oriented
women are likely to be representative of postmenopausal oestrogen users while they are not representative of all women (e.g. members
of a health maintenance organisation (HMO) will be a representative sample of oestrogen users. While the HMO may have an under-
representation of ethnic groups, the poor, and poorly educated, these excluded groups are not the predominant users of oestrogen).
Allocation of stars as per rating sheet
2. Selection of the non-exposed cohort
Allocation of stars as per rating sheet.
3. Ascertainment of exposure
Allocation of stars as per rating sheet.
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4. Demonstration that outcome of interest was not present at start of study
In the case of mortality studies, outcome of interest is still the presence of a disease/incident, rather than death. That is to say that a
statement of no history of disease or incident earns a star.
Comparability
1. Comparability of cohorts on the basis of the design or analysis
A maximum of 2 stars can be allotted in this category. Either exposed and non-exposed individuals must be matched in the design
and/or confounders must be adjusted for in the analysis. Statements of no differences between groups or that differences were not
statistically significant are not sufficient for establishing comparability. Note: If the relative risk for the exposure of interest is adjusted
for the confounders listed, then the groups will be considered to be comparable on each variable used in the adjustment. There may
be multiple ratings for this item for different categories of exposure (e.g. ever vs. never, current vs. previous or never) Age = , Other
controlled factors =
Outcome
1. Assessment of outcome
For some outcomes (e.g. fractured hip), reference to the medical record is sufficient to satisfy the requirement for confirmation of the
fracture. This would not be adequate for vertebral fracture outcomes where reference to x-rays would be required.
Independent or blind assessment stated in the paper, or confirmation of the outcome by reference to secure records (X-rays, medical
records, etc.)
Record linkage (e.g. identified through ICD codes on database records)
Self-report (i.e. no reference to original medical records or X-rays to confirm the outcome)
No description.
2. Was follow-up long enough for outcomes to occur
An acceptable length of time should be decided before quality assessment begins (e.g. 5 yrs. for exposure to breast implants)
3. Adequacy of follow-up of cohorts
This item assesses the follow-up of the exposed and non-exposed cohorts to ensure that losses are not related to either the exposure or
the outcome.
Allocation of stars as per rating sheet.
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